EICHORPublic-registry site landscape for NCT03504488, “CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)”, a Non Small Cell Lung Cancer study sponsored by BioAtla, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03504488 (registry record) |
| Study title | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) |
| Official title | A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2) |
| Sponsor | BioAtla, Inc. |
| Condition(s) | Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Melanoma; Head and Neck Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 59 |
| Site countries | United States, Greece, Hong Kong, Poland, Spain, Taiwan |
Patient-friendly overview of this study: eichor.com/study/NCT03504488.
Eichor generates a preliminary site-risk snapshot for NCT03504488 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Non Small Cell Lung Cancer trials
More from BioAtla, Inc.
← Eichor home · All tracked trials · Non Small Cell Lung Cancer studies · Weekly briefs
